Quoc Pham
Family · Anaheim, CANPI 1275908832
Payments from drug & device makers
Across 109 payments — averaging $19.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$344
- Takeda Pharmaceuticals U.S.A., Inc.$285
- Johnson & Johnson$209
- Amarin Pharma, Inc.$189
- Novo Nordisk$165
- Amgen$144
- plus $820 from 15 others
What the payments were for
- Food & beverage$2,157100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 25 | $344 |
| Takeda Pharmaceuticals U.S.A., Inc. | 13 | $285 |
| Johnson & Johnson | 12 | $209 |
| Amarin Pharma, Inc. | 8 | $189 |
| Novo Nordisk | 11 | $165 |
| Amgen | 7 | $144 |
| Nestle Healthcare Nutrition Inc. | 6 | $144 |
| Pfizer | 5 | $118 |
| Corcept Therapeutics | 1 | $112 |
| Kowa Pharmaceuticals America, Inc. | 3 | $64 |
| Lilly USA, LLC | 3 | $62 |
| Merck | 2 | $48 |
| GSK | 2 | $46 |
| Ironwood Pharmaceuticals, Inc | 2 | $44 |
| Genentech USA, Inc. | 2 | $42 |
| AstraZeneca | 2 | $40 |
| Boehringer Ingelheim | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $18 |
| Alkermes, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$112
How this compares
$2,157 in reported general payments places this provider in the 85th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $19,216 |
| TrulicityDulaglutide | 12 | $13,757 |
| MounjaroTirzepatide | 11 | $11,870 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 13 | $9,794 |
| Cyclosporine | 13 | $6,910 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 32 | $6,808 |
| Lubiprostone | 21 | $3,973 |
| VascepaIcosapent Ethyl | 11 | $3,747 |
| Lidocaine | 17 | $1,607 |
| Levocetirizine Dihydrochloride | 31 | $803 |
| Rosuvastatin Calcium | 26 | $478 |
| Azelastine Hcl | 11 | $469 |
| Gabapentin | 39 | $439 |
| Ipratropium Bromide | 11 | $298 |
| Famotidine | 24 | $277 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanumet, Janumet Xr | $48 | $29,01028 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $62 | $25,62723 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,634 family providers in California.
Other family in Anaheim
- Sofia KimAnaheim$32K
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.